Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on <i>UGT1A1</i> Genotypes: A Systematic Review

Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on <i>UGT1A1</i> Genotypes: A Systematic Review

<b>Background/Objectives:</b> Irinotecan is used in monotherapy or combined with other drugs for treating different cancer streams. SN-38, the active metabolite of irinotecan, is 70% inactivated by the uridine diphosphate (UDP) glucuronosyltransferase family 1 member A1 (UGT1A1) enzyme....

Full description

Saved in:
Bibliographic Details
Main Authors: Xando Díaz-Villamarín, María Teresa Nieto-Sánchez, María Martínez-Pérez, Paula Novo-González, Emilio Fernández-Varón, Alicia Torres-García, Beatriz González Astorga, Isabel Blancas, José Cabeza-Barrera, Rocío Morón
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Pharmaceutics
Subjects:
irinotecan
<i>UGT1A1</i>
maximum tolerated dose
pharmacogenetics
pharmacogenomic
personalized medicine
Online Access:https://www.mdpi.com/1999-4923/17/5/542
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1999-4923/17/5/542

Similar Items